Format

Send to

Choose Destination
Int J Surg. 2018 Dec;60:216-223. doi: 10.1016/j.ijsu.2018.11.020. Epub 2018 Nov 20.

Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: A meta-analysis of results from multivariate analysis.

Author information

1
Department of Urology/Shenzhen Urology Minimally Invasive Engineering Center, The Second Clinical Medical College of Jinan University/Shenzhen People's Hospital, Shenzhen, Guangdong Province, China; The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Shenzhen Cell Therapy Public Service Platform, Shenzhen, Guangdong Province, China.
2
The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Shenzhen Cell Therapy Public Service Platform, Shenzhen, Guangdong Province, China; Clinical Medical Research Center, Shenzhen People's Hospital, Shenzhen, Guangdong Province, China.
3
Department of Urology/Shenzhen Urology Minimally Invasive Engineering Center, The Second Clinical Medical College of Jinan University/Shenzhen People's Hospital, Shenzhen, Guangdong Province, China; The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Shenzhen Cell Therapy Public Service Platform, Shenzhen, Guangdong Province, China. Electronic address: kevin5510315@qq.com.
4
The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Shenzhen Cell Therapy Public Service Platform, Shenzhen, Guangdong Province, China. Electronic address: wangjianhong0755@163.com.

Abstract

BACKGROUND:

The prognostic role of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in patients with prostate cancer (PCa) remains inconsistent. Here we quantify the prognostic impact of these biomarkers and assess their consistency in PCa.

MATERIALS AND METHODS:

We systematically searched PubMed, Web of Science, and Embase for eligible studies embracing multivariate results. The Newcastle-Ottawa Scale were used to assess the study quality. Pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated.

RESULTS:

A total of 7228 patients from 18 studies were included in the meta-analysis. Overall, elevated pretreatment NLR was associated with poor overall survival (OS, HR 1.58, 95% CI 1.41-1.78, P < 0.001), progression-free survival (PFS, HR 1.95, 95% CI 1.53-2.49, P < 0.001) and biochemical recurrence-free survival (BRFS, HR 1.37, 95% CI 1.07-1.75, P = 0.011). And high pretreatment PLR was correlated with more inferior PFS (HR 1.62, 95% CI 1.20-2.19, P = 0.002), OS (HR 1.70, 95% CI 1.34-2.15, P < 0.001) and cancer-specific survival (CSS, HR 2.02, 95% CI 1.24-3.29, P = 0.005). Moreover, the subgroup analyses did not alter the direction of results for OS and PFS.

CONCLUSION:

Based on these findings, elevated NLR and PLR was associated with poor oncologic outcomes, and they can serve as prognostic factors in PCa patients.

KEYWORDS:

Inflammation; Meta-analysis; Neutrophil to lymphocyte ratio; Platelet to lymphocyte ratio; Prognosis; Prostate cancer

PMID:
30468905
DOI:
10.1016/j.ijsu.2018.11.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center